Sign inJoin waitlistJoin the waitlist

AR

Arlene Redner

Physician · Northwell Health

Credentials: · ·

History

Northwell Health
2019–Present

Pediatric Hematology/Oncology
Zucker School of Medicine at Hofstra/Northwell
1980–1983
Pediatrics
1977–1980
The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania
1973–1977

Research

Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization
Science · 1990 · 364 citations
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias
Journal of Clinical Oncology · 1993 · 118 citations
Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol
Cancer · 1993 · 79 citations

Michael Andreeff
6 papers
PS
Peter Steinherz
5 papers
Morris Edelman
3 papers
PM
Paul Meyers
3 papers
AS
Ashok Shende
2 papers
CP
Carole Paley
2 papers
Mark Atlas
2 papers
MM
Myron Melamed
2 papers
PL
Philip Lanzkowsky
2 papers
Vincent Bonagura
2 papers
AF
Adiel Fleischer
1 paper
AJ
Alan Johnson
1 paper

Clinical trials

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Site PI · Recruiting · Phase 1, Phase 2
PedAL BCU, LLC
2022–2030
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Site PI · Recruiting · Phase 3
Children's Oncology Group
2020–2029
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Site PI · Recruiting · Phase 3
Children's Oncology Group
2019–2032